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Surgical site infections (SSI) can develop post-operatively and carry significant clinical 
and financial implications. SSI can carry a cost of up to $30,000 per case, as well as an 
estimated 6 day longer hospitalization. Patients with Type II Diabetes (DM) have an 
increased susceptibility to infection and suffer from poor bone healing overall. Therefore, 
diabetic patients who have undergone orthopedic surgery risk both an increased chance of 
developing an SSI as well as suboptimal bone healing. Vancomycin and other antibiotics 
have traditionally been used prophylactically to prevent infection, however the effect of 
vancomycin on bone healing in a diabetic population has not been well documented. 
Periosteum derived osteoblasts were treated with BMP-2, and vancomycin concentrations 
of 0 ug/mL, 5 ug/mL, 50 ug/mL, 500 ug/mL, and 5,000 ug/mL. The purpose of this work 
was to examine the effects, if any, that vancomycin had on periosteum derived osteoblast 
precursor functions including calcium deposition, osteoblast differentiation, and cell 
viability. Continuously dosed osteoblasts at a concentration of 5,000 ug/mL had a 3-fold 
decrease in calcium deposition when compared to the BMP-2 treated group (P<0.005). In 
addition, cell proliferation was significantly decreased by 33% at a dosage of 5,000 
ug/mL 24 hours post treatment (P<0.005). Finally, a 3-fold decrease in osteoblast 
differentiation was seen when continuously dosed at 5,000 ug/mL (P<0.005). However, 
these effects seen at 5,000 ug/mL are well above the mean inhibitory concentration for 
resistant MRSA infections of 16 ug/mL. Therefore, clinically appropriate dosages of 
topical vancomycin can be used prophylactically in the diabetic patient, without concern 





The Importance of Studying Antibiotics as Treatment for SSI Infections 
Surgical site infections (SSI) are costly post-operative complications with 
negative financial and clinical consequences. Financially, treatment of SSI is estimated to 
cost between $400 and $30,000 per case in the United States (Urban 2006). Clinically, 
surgical site infections have consequences including prolonged hospitalization, extended 
recovery time, and increased cost of post-operative care (Qadir et al., 2021). Kirkland et 
al., performed a follow up study of patients admitted to a 415-bed community hospital 
and found that patients who developed SSI had an approximately 6 days longer stay with 
an estimated $3,000 in additional costs (Kirkland et al. 1999). The importance of using 
antibiotics as a treatment cannot be understated as a meta-analysis done by AlBuhairan et 
al, found that antibiotic prophylaxis reduced the relative risk of infection by 81% to those 
untreated individuals following joint arthroplasty (AlBuhairan et al., 2008). Given the 
increased implications from SSI and the effectiveness of antibiotic prophylaxis, 
determining effective and safe usage of these antibiotics is of utmost importance.  
Stages of Bone Fracture Healing  
The understanding of bone repair is important, not only for the treatment of minor 
fractures as a result of injuries, but also for effective management of those with 
comorbidities affecting bone healing (Office of the Surgeon General, 2004). Bone 
fracture healing can be separated into four distinct steps: hematoma formation, 




In humans, bone healing begins with the formation of a hematoma immediately 
following fracture or injury and lasts about 5 days. The initial trauma to the area will 
rupture the blood vessels and periosteum around the site and cause a collection of blood, 
or hematoma, to form around the fracture. This hematoma will form the initial framework 
for subsequent repair. It is during this period in which a multitude of proinflammatory 
cytokines including tumor necrosis factor alpha (TNF-alpha), bone morphogenic proteins 
(BMPs), and interleukins will be upregulated (Sheen and Garla 2021). It is these factors 
that will recruit inflammatory cells and promote angiogenesis or the formation of new 
blood vessels. (Marsell and Einhorn 2011). IL-6 will specifically stimulate angiogenesis 
as well as vascular endothelial growth factor (VEGF) which will drive the next step, 
fibrocartilaginous formation.  
The next step of the fracture healing process, taking place on days 5 to 11 post 
injury, involves the recruitment of mesenchymal stem cells (MSC) (Marsell and Einhorn, 
2011). MSCs recruited to the fracture site proliferate and differentiate into the cells 
needed for chondrogenesis, specifically chondrocytes (Granero-Moltó et al., 2008). In 
addition, the disruption of the local vasculature results in a hypoxic state, which aids in 
the differentiation of the recruited MSCs towards the chondrogenic, cartilage building, 
pathway and results in the formation of a cartilaginous callus. (Loi et al., 2016). This 
cartilaginous tissue provides a microenvironment that favors chondrocyte differentiation, 
while preventing osteoblast function (Claes et al., 2012). Additionally, the low oxygen 
state promotes revascularization and neo-angiogenesis at the fracture site. Throughout 




additional MSCs. The recruitment of these stem cells will result in the formation of 
fibrin-rich granulation tissue and subsequently lead to the formation of a soft callus. 
The soft callus, at this time made of cartilage, will then undergo endochondral 
ossification and be replaced by bone from days 11 to 28. The replacement of cartilage 
first begins with the resorption of the soft callus and subsequent calcification by 
osteoblasts and osteoclasts. By the end of these steps the soft callus will be replaced by a 
hard bony callus and closure of the fracture (Marsell and Einhorn 2011). The last, and 
longest step, of bone fracture healing is known as bone remodeling. The hard callus itself 
is not mature bone and further bone resorption by osteoclasts and bone deposition by 
osteoblasts will replace the callus with compact bone and the edges of the callus will be 
replaced by lamellar bone. Most notably, this step can last anywhere from months to 
years to fully regenerate the bone.  
Inflammation And Its Relationship to Poor Bone Fracture Healing  
The immune system and its components make critical chemical messengers that 
aid in the stimulation of osteogenesis when an external trauma triggers acute 
inflammation. However, in a chronically inflamed environment, including disease states 
such as diabetes mellitus (DM), inflammation can disrupt osteogenesis (Claes et al, 
2012). It is important to note that the fracture healing processes described prior are under 
ideal conditions, with an appropriate inflammatory response. Problems arise when 
chronic inflammatory disease states caused by rheumatoid arthritis (RA), chronic 




erythematosus (SLE) coexist during bone fracture (Claes et al, 2012). Chronic 
inflammation results in the upregulation of TNF-alpha and NF-kβ signaling pathways. 
This in turn increases osteoclast resorption, which contributes to excessive bone loss and 
poor bone fracture healing (Maruyama et al., 2020). Data also demonstrates that 
increased inflammatory state will lead to the amplified recruitment of neutrophils into the 
fracture site, which stimulates chondrogenesis, but inhibits osteogenesis (Bastian et al. 
2018).  
Type II DM, SSI Relationship, And Impaired Bone Healing  
Type II DM is often associated with a higher risk of infection for a variety of 
different surgical procedures including cardiothoracic, gastrointestinal, and most notably 
orthopedic. Olsen et al. performed a retrospective case-control study of patients following 
orthopedic surgery and found that diabetic patients, specifically those with elevated 
serum glucose levels indicative of diabetes, had the highest independent risk of 
developing a SSI, as indicated by an odds-ratio of 3.5 (Olsen et al., 2008).  Latham et al. 
additionally found that diabetic patients, both diagnosed and undiagnosed, had an 
increased association with the development of surgical site infections (Latham et al., 
2001). These surgical site infections specifically inhibit callus formation and instead 
causes the formation of fibrous tissue. This in turn will lead to decreased mechanical 
stability and overall poor fracture healing (Croes et al. 2019). Interestingly, undetected 
non-union of fractures have been assumed to have been caused by low grade infections 




Vancomycin As a Treatment For SSI  
Postoperative infection following orthopedic surgery is a concern that is most 
mitigated using topical antibiotics. Many times, the antibiotic may be either topical 
vancomycin, tobramycin, or a combination of both (Owen et al., 2017). Vancomycin 
prevents bacterial growth by inhibiting bacterial cell wall production, specifically the 
polymerization of peptidoglycans (Watanakunakorn 1984). It is especially effective in 
preventing infections by gram-positive bacteria, and more importantly methicillin- 
resistant Staphylococcus aureus (MRSA) (Patel et al., 2020.)  As per the CDC, MRSA 
strains with decreased susceptibility to vancomycin have a vancomycin MIC of 4-8 
µg/mL, whereas resistant strains have a vancomycin MIC greater than 16 µg/mL 
Versalovic et al., 2011). Although systemic use of vancomycin in preventing bacterial 
infections is common, the use of topical vancomycin powder in preventing surgical site 
infections (SSI) after orthopedic procedures has not yet been approved by the U.S Food 
and Drug Administration (Takahashi et al., 2018). However, research does support the 
local administration of vancomycin.  Kanj et al. found that orthopedic surgery patients 
who receive local vancomycin were 4 times less likely to develop a deep postoperative 
wound infection, when compared to those untreated patients (Kanj et al., 2013). In a 
retrospective review of 272 patients, with groups consisting of standard intravenous 
antibiotics and topical vancomycin, 6 patients from the standard treatment group 
developed an infection, compared to none in the vancomycin group. With a P=0.0027 it 
was found that there was indeed a statistical difference in treatment types (Yan et al., 




without topical vancomycin was assessed. It was found that none of the 35 patients (0% 
infection rate) treated with vancomycin developed an infection, compared to 58/548 
(10.6% infection rate) patients not treated with vancomycin, thereby providing further 
support for the use of topical antibiotics (Qadir et al., 2021). Although the efficacy of 
topical antibiotic powder to reduce infection is well documented, it is less clear whether it 
negatively impacts osteogenesis.  
Vancomycin and Osteogenesis  
Current data examining vancomycin treatment and osteogenesis in vitro are 
unclear. Yu et al’s studied bone marrow stromal cells (BMSCs) incubated in vancomycin, 
tobramycin, and both over 7 days. The study found the local administration of 
vancomycin (14.28 ug/mL), tobramycin (28.57 ug/mL) or the combination of the two 
(vancomycin 14.28 ug/mL, tobramycin 28.57 ug/mL) did not negatively impact cell 
viability or proliferation. (Yu et al., 2020). Edin et al. cultured MG-63 human 
osteosarcoma cells in vancomycin at concentrations of 0, 10, 100, 1000, and 1000 ug/mL 
with analysis at 0, 24, and 72 hours of treatment. Their results indicated a significant 
decrease in cell growth at a vancomycin concentration of 10,000 ug/mL at the 24- and 
72-hour time points. However, increases in cell death were not noted at the lower 
concentrations. (Edin et al., 1996). In contrast, Braun et al. explored the effects of human 
primary osteoblasts at concentrations of 10, 100, 200, 500, 1000, and 2000 ug/mL at days 
1, 3, 5, and 10. They found that human primary osteoblasts had decreased proliferation on 
day 1 at a concentration of 2 mg/mL. However, increasing concentrations beginning from 




In vivo studies focused on the effect of vancomycin and bone are limited. One in 
vivo study examined posterolateral lumbar spinal fusion of 36 rats divided into three 
treatment groups including: no vancomycin, standard dose vancomycin (14.3 mg/kg) and 
high dose vancomycin (143 mg/kg). They found that there were no significant differences 
in spinal fusion across both treatment groups when compared to the control. In addition, 
microCT data demonstrated no differences in volume of newly generated bone of the 
vancomycin groups (both standard and high dose) when compared to control. This data 
provided compelling evidence that vancomycin treatment may not negatively affect 
osteogenesis (Mendoza et al, 2016). In a clinical setting examining systemic effects, 
Owen et al., performed a retrospective study to determine the incidence of SSI after 
pelvic ring and acetabulum fracture surgery. They found that the risk of infection in the 
patients treated with 1g vancomycin and 1.2g tobramycin powder had a 4.2% risk of 
infection, significantly less than that of the untreated group which was 14.5% (Owen et 
al, 2017).   
The importance of effectively reducing SSI in Type I DM cannot be understated 
as improvement in this area can both improve patient and economic outcomes (Potter, 
2018).  Our research aims to determine clinically relevant dosages of vancomycin that 
will not inhibit osteoblast cellular functions.  More specifically, we hypothesized that the 
vancomycin doses that are effective at treating infection (<16ug/mL) will not negatively 






Materials and Methods 
Bone Marrow Cell Isolation  
The femora of 3-month-old BB Wistar Type I DM rats were resected. The distal 
and proximal ends of the femurs were cut, to expose the bone marrow. A 16G needle was 
inserted into one end of the femur and the marrow was subsequently flushed using 5 mL 
of α-MEM, supplemented with 10% v/v FBS and 0.5% v/v penicillin-streptomycin. The 
femur was inverted and flushed with an additional 5 mL of PBS. The cells were cultured 
undisturbed at 37oC, 5% CO2 for 48 hours and then the adherent cells were sub-cultured 
for use in experiments. 
Periosteum Cell Isolation 
The tibia and fibula of 3 month old BB Wistar Type I DM rats were resected. 
Muscle and other tissues were carefully cut from the isolated bone. The periosteum was 
then gently scraped off and placed cambium side down onto a 100 mm culture dish. PBS 
supplemented with 1% v/v fungizone, and 0.5% v/v penicillin-streptomycin was used to 
wash the samples three times. Afterwards the periosteum samples were placed onto a 
100mm culture dish without media and incubated at 37oC, 5% CO2 for 5 mins to allow 
the tissue to adhere to the plate. Once adhered, the isolated periosteum was cultured in α-
MEM supplemented with 10% v/v FBS, 0.5% v/v penicillin-streptomycin, 1% v/v 
fungizone at 37oC, 5% C02 [25]. Media was changed every 2 days until migration of cells 
from the periosteum samples was visualized. The periosteum remnants were then 
removed, and the cells were cultured until confluency, approximately every 7 days. Cells 




Osteogenic Differentiation and Treatment Groups 
Rat bone marrow cells and periosteum cells were cultured α-MEM supplemented 
with 10% v/v FBS, 0.5% v/v penicillin-streptomycin, 1% v/v fungizone, 10 mM ß-
glycerophosphate and 100 µM L-ascorbic acid to induce osteogenic differentiation [26]. 
After the cell cultures reached confluence, vancomycin was added to the osteogenic 
media at 0, 5, 50, 500, or 5,000 µg/mL. Single dose (SD) cultures were treated with 
vancomycin for 48 after confluence and then returned to osteogenic media without 
vancomycin till the experimental endpoint. Once confluent, continuous dosing (CD) 
cultures were switched into and maintained in vancomycin supplemented osteogenic 
media until the experimental endpoint. BMP-2 (10 ng/mL) was added to osteogenic 
media as a positive control and used for an alkaline phosphatase assay, alizarin red 
staining and MTT assay.  
MTT Assay  
Periosteum cells were seeded, in triplicate, onto a 96 well dish at a seeding 
density of 5.0 x104 cells/mL in standard culture medium and allowed to attach overnight.  
After confirming adherence, the media was replaced with vancomycin at increasing 
concentrations (0, 5, 50, 500, 5000 ug/mL) and cells were incubated at 37°C and 5% 
CO2.  After 24-hours of treatment, media was aspirated from each well and replaced with 
MTT solution and incubated at 37°C, 5% CO2 for 2 hours.  Three volumes of DMSO 
were added to each well and the plate was incubated on an orbital shaker for 30 minutes 




crystals dissolved into the DMSO solvent.   The absorbance of each well was detected on 
a spectrophotometer (Thermo-Fisher Waltham, Massachusetts) at an O.D of 590nm.  
 
Alizarin Red Staining  
Calcium deposition in the cell cultures was measured after 14- and 28-days using 
Alizarin Red S staining in triplicate. Media was carefully aspirated from each culture and 
the cells were washed 2 times with PBS before fixing in 0.5 mL of 10% formaldehyde for 
15 minutes at room temperature. The formaldehyde was removed, and the fixed cells 
were washed 2 times with PBS before adding 1 mL of 40 mM Alizarin Red Stain (ARS). 
Cultures were incubated at room temperature for 20 minutes with gentle shaking. The 
stained cultures were washed with water 4 times. To each culture well, 0.8 mL of 10% 
acetic acid was added and incubated at room temperature for 30 mins with gently 
shaking. The culture extract was transferred to a microcentrifuge tube and any remaining, 
adherent cells were scraped from the culture well and added to the microcentrifuge tube. 
The samples were then vortexed for 30 seconds, heated at 85oC for 10 mins, and 
transferred to ice for 5 minutes. Debris was removed by centrifugation (20,000 g for 15 
minutes). An aliquot of the supernatant (500 µL) was transferred into a new 
microcentrifuge tube to which 200 µL of 10% (v/v) of ammonium hydroxide was added. 
Aliquots of the neutralized extract (150 µL) were transferred into a 96-well plate and the 
absorbance was measured on a spectrophotometer (Thermo-Fisher Waltham, 





Alkaline Phosphatase Assay 
Alkaline phosphatase activity was measured in media aliquots using the 
colorimetric para-nitro-phenyl phosphate (pNPP) assay with reagents obtained from 
Sigma-Aldrich (St. Louis, MO). Media was collected from cell cultures at 7, 14, 21, and 























Figure 1. Periosteum Cell Viability via MTT Assay. As indicated above there was 
statistically significant cell toxicity in the samples treated with a dosage of 5000 ug/mL 
when compared to control and lesser dosages. There is no difference in each of the 
treatment groups against one another, or when compared to the untreated, control, group. 






Vancomycin’s Effect on Cellular Proliferation 
Periosteum proliferation was significantly decreased by 33% at a dosage of 5,000 ug/mL 
24 hours post treatment, when compared to 0, 50, and 500 ug/mL doses (Figure 1). A 
slight increase in proliferation was seen with increasing vancomycin dosages (5ug/mL to 
500 ug/mL) when compared to the untreated group although it is found to not be 
statistical significant. This therefore indicates that at a concentration of 5,000 ug/mL, 












Figure 2. Two- and Four-Week Alizarin Red Staining of Periosteum Derived 
Osteoblasts. Calcium deposition levels were observed (Panels C through G) and 
quantified via spectrometry reading at 405nm at week 2 (Panel A) and week 4 (Panel B). 
Quantification of the staining reveals a statistically significant (P<0.005) decreased 
calcium deposition in vancomycin dosages of 5000 ug/mL SD and CD. Panel C 
demonstrates positive control with BMP-2 treatment. Panel D demonstrates growth with 
osteogenic media, but no treatment. Panels E-G are from continuously dosed samples. All 
treatment types, SD and CD, had decreased calcium deposition values when compared to 
the control treated group. However, no difference was noted between the control and 50 






























Vancomycin’s Effect on Calcium Deposition  
Alizarin red is stain used to indicate calcium deposits in culture, and in this experiment 
was used to detect overall calcium deposition, with more visible staining indicating 
increased calcium deposition by the differentiated osteoblasts. As expected, the positive 
control, BMP-2 treatment resulted in a 40% significant increase in calcium deposition 
when compared to 0 ug mL, 50 ug/mL, 500 ug/mL, and 5,000 ug/mL (Figure 2, 
P<0.005). At day 14 there was a 3-fold decrease in calcium deposition from both the 
single and continuously dosed 5,000 ug/mL treatment groups (P<0.005). However, at day 
28, there was only a 3-fold decrease in calcium deposition at CD 5,000 ug/mL 
vancomycin.  Interestingly, the SD 5,000 ug/mL vancomycin treated group, which 
initially demonstrated an 80% decrease in calcium deposition on day 14, had recovered to 
levels like the control and remaining treatment groups by day 28. Overall, there was an 
increase in calcium deposition seen in all the treatment groups, including the CD 5,000 






Figure 3.  Alkaline Phosphatase Activity Following Treatment with Vancomycin. 
Alkaline phosphate activity at days 7, 14, 21, and 28. At all-time points there is a 
statistically significant decrease in ALP activity when continuously dosed (CD) at a 
concentration of 5,000 ug/mL. Lower concentration groups, both continuously dosed and 
single dosed, demonstrate no decrease in activity. Statistical significance is defined as 
P<0. 005.Similar ALP levels are noted throughout control samples, with BMP-2, 





Vancomycin’s Effect on Osteogenic Differentiation  
Alkaline phosphatase (ALP) has generally been regarded as an early marker for 
assessment of osteoblast differentiation, with increased detection of ALP indicating 
increased differentiation. ALP can be regarded as a marker since it is a byproduct of 
osteoblast activity and therefore indicative of active differentiated osteoblasts. Periosteum 
cells continuously dosed at a concentration of 5,000 ug/mL showed a statistically 
significant decrease in osteogenic differentiation, as assessed through decreased ALP 
activity (P<0.005, Figure 3). Single dosed samples at 5,000 ug/mL did not reveal 
decreased ALP activity when compared to the controls or lower dosages throughout the 
28-day timepoint. At day 21 and 28, a 3-fold decrease in ALP activity at 5,000 ug/mL 
was found when compared to lower dosages and control (P<0.005). SD and CD 
periosteum cells from 5 to 500 ug/mL maintained similar values when compared to the 
control treatment group throughout all time points.  It is important to note however, that 




These results indicate that at clinically appropriate dosages, referenced by the 
CDC as an MIC greater than 16 ug/mL for MRSA strains, do not inhibit osteoblast 
cellular functions or proliferation. As shown, concentrations of vancomycin up to 500 
ug/mL do not demonstrate decreased proliferation, calcium deposition, or osteoblast 




indicating no decrease in osteoblast viability or mesenchymal stem cell differentiation 
(Booysen et al., 2018). Liu et al., explored concentrations beyond 1000 ug/cm2, including 
3000, 6000, and 12000 ug/cm2 and found that continuous exposure to concentration of 
vancomycin greater than 1mg/cm2 results in decreased viability 48 hours post exposure. 
However, they also showed that short exposure, defined as 1 hour, to concentrations of 
1000 to 6000 ug/ cm2 had no decreased cell migration or cell survivability (Liu et al 
2018).  Here we indicated a significantly increased dose of 5,000 ug/mL will not cause 
detrimental effects to the osteoblasts, when treated with only an initial dose (Figures 1, 2 
and 3). Baun et al. determined that vancomycin treatment with concentrations up to 
1mg/mL (1000 ug/mL) will not result in decreased cell viability or decreased ALP 
activity. Edin et al., also determined that concentrations up to 1000 ug/mL did not 
demonstrate inhibition of osteoblast replication. They did however note cell death when 
using concentrations of 10,000 ug/mL. As shown here, a continual dosage of 5000 ug/mL 
does indeed inhibit cell proliferation, calcium deposition, and ALP activity (Figure 3). 
Sakamoto et al., did demonstrate that vancomycin concentrations greater than 2 mM can 
have a detrimental effect in LLK-PK1 cells (renal tubular epithelial cells), specifically the 
mitochondria (Sakamoto et al., 2017). This research suggest that high doses of 
vancomycin may impact the mitochondria of local cells like osteoblasts.  Further research 
is necessary to validate this finding.    
It is important to note that concentrations used (50, 500, and 5000 ug/mL) are 
well above the mean inhibitory concentrations necessary for antimicrobial activity. As 




inhibitory concentration (MIC) of 4-8 ug/mL, whereas resistant strains have an MIC 
greater than 16 ug/mL. Therefore, both the 5 ug/mL and 50 ug/mL are both well in the 
range of successfully preventing resistant MRSA infections. As discussed, the pro-
inflammatory state of diabetic patients results in poor fracture healing overall. In 
addition, diabetic patients also have an increased risk of developing infections, infections 
which themselves result in poor bone healing. This research aims to provide merit for an 
additional form of infection control in patients with increased susceptibility to both 
infection and poor bone healing. We have shown that single doses of up to 5,000 ug/mL 
do not have any detrimental effects to the periosteum derived osteoblasts.  
Interestingly, this data shows that although a single dose of 5,000 ug/mL does 
decrease calcium deposition at day 14, by day 28 the osteoblasts recover, with calcium 
deposition comparable to the control (Figure 3). This could indicate that this initially high 
dose potentially diffuses from the site, and the cells are able to recover and function as 
normally. However, the importance of using lower effective ranges, with no detrimental 
effect to the osteoblasts cannot be understated. Further in vivo work would also need to 
complete to determine if local administration of vancomycin can lead to systemic effects 
as observed with intravenous vancomycin administration.  
 
Conclusion 
Clinically appropriate dosages of vancomycin do not affect periosteum 
differentiation or function. However, a continuous dose of 5000 ug/mL does inhibit 
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